A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity

BACKGROUND: Pertuzumab is currently used in combination with trastuzumab as the first-line treatment for HER2-positive metastatic breast cancer. However, pertuzumab was originally developed independently from trastuzumab and was later incidentally found to have synergistic efficacy when combined wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xiaoyu, Gu, Wanjian, Zhong, Yujie, Hao, Xiaoyao, Liu, Jinyu, Xia, Shukai, Luo, Lan, Chen, Mingjiu, Zhang, Chunni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501074/
https://www.ncbi.nlm.nih.gov/pubmed/32950002
http://dx.doi.org/10.1016/j.ebiom.2020.102996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501074/
https://www.ncbi.nlm.nih.gov/pubmed/32950002
http://dx.doi.org/10.1016/j.ebiom.2020.102996

Ejemplares similares